HMG20B 抗体 (AA 1-100) (AbBy Fluor® 750)
Quick Overview for HMG20B 抗体 (AA 1-100) (AbBy Fluor® 750) (ABIN4997589)
抗原
See all HMG20B 抗体适用
宿主
克隆类型
标记
应用范围
- 
    - 
                                            抗原表位
- AA 1-100
- 
                                            交叉反应
- 小鼠
- 
                                            预测反应
- Human,Rat,Cow
- 
                                            纯化方法
- Purified by Protein A.
- 
                                            免疫原
- KLH conjugated synthetic peptide derived from human BRAF35
- 
                                            亚型
- IgG
 
- 
                                            
- 
    
- 
    - 
                                            应用备注
- 
                        IF(IHC-P) 1:50-200
 IF(IHC-F) 1:50-200
 IF(ICC) 1:50-200
- 
                                            限制
- 仅限研究用
 
- 
                                            
- 
    - 
                                            状态
- Liquid
- 
                                            浓度
- 1 μg/μL
- 
                                            缓冲液
- Aqueous buffered solution containing 0.01M TBS ( pH 7.4) with 1 % BSA, 0.03 % Proclin300 and 50 % Glycerol.
- 
                                            储存液
- ProClin
- 
                                            注意事项
- This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE, which should be handled by trained staff only.
- 
                                            储存条件
- -20 °C
- 
                                            储存方法
- Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles.
- 
                                            有效期
- 12 months
 
- 
                                            
- 
    - HMG20B (High Mobility Group 20B (HMG20B))
- 
                                            别名
- BRAF35
- 
                                            背景
- 
                        Synonyms: BRAF25, BRAF35, BRCA 2 Associated Factor 35 kDa, BRCA2 associated factor 35, BRCA2-associated factor 35, High Mobility Group Protein 20B, HM20B_HUMAN, HMG 20B, HMG box containing protein 20B, HMG box-containing protein 20B, HMG domain-containing protein 2, HMG domain-containing protein HMGX2, hmg20b, HMGX2, PP7706, pp8857, SMARCE1 related protein, SMARCE1-related protein, SMARCE1r, sox like, Sox like transcriptional factor, Sox-like transcriptional factor, SOXL, Structural DNA binding protein BRAF35, Structural DNA-binding protein BRAF35, SWI/SNF related, SWI/SNF related matrix associated actin dependent regulator of chromatin subfamily E member 1 related, SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily E member 1-related. Background: The breast cancer susceptibility gene (BRCA1) localizes to chromosome 17q. Mutations within this gene account for approximately 45 % of families with high incidence of breast cancer and at least 80 % of families with increased incidence of both early-onset breast cancer and ovarian cancer. A second breast cancer susceptibility gene, BRCA2, located on chromosome 13q12-13, also confers a high incidence of breast cancer, but unlike BRCA1, BRCA2 does not confer a substantially elevated risk of ovarian cancer. The BRCA2-Associated Factor 35 (BRAF35) protein forms a complex with BRCA2, which associates with condensed chromatin during histone H3 phosphorylation. BRAF35 expression levels are highest in proliferating tissues and parallel BRCA2 expression patterns. The structure of BRAF35 includes a kinesin-like coiled coil domain and a nonspecific DNA binding HMG domain. The chromatin localization of BRAF35 and antibody microinjection studies indicate a role for the BRAF35/BRCA2 complex in cell cycle regulation. 
- 
                                            基因ID
- 10362
 抗原
- 
                    
 
                                     
                                     
                                    